Tweet
Company Profile:
ACADIA Pharmaceuticals, Inc.
3911 Sorrento Valley Boulevard
San Diego, CA 92121
United States - Map
Phone: 858-558-2871
Fax: 858-558-2872
Website: http://www.acadia-pharm.com
Details:
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 27
Business Summary:
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson's disease psychosis. It is also developing AGN-XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development in collaboration with Meiji Seika Kaisha, Ltd. In addition, ACADIA Pharmaceuticals Inc. is developing two preclinical programs in the area of Parkinson’s disease. The product candidates in the company’s pipeline emanate from discoveries made using its proprietary drug discovery platform. The company was founded in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals, Inc.
3911 Sorrento Valley Boulevard
San Diego, CA 92121
United States - Map
Phone: 858-558-2871
Fax: 858-558-2872
Website: http://www.acadia-pharm.com
Details:
Index Membership: N/A
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 27
Business Summary:
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company has a portfolio of four product candidates, including pimavanserin, which is in Phase III clinical development as a treatment for Parkinson's disease psychosis. It is also developing AGN-XX/YY, a product candidate in Phase II for chronic pain; and AC-262271, a product candidate in Phase I for glaucoma in collaboration with Allergan, as well as AM-831, a product candidate in IND-track development in collaboration with Meiji Seika Kaisha, Ltd. In addition, ACADIA Pharmaceuticals Inc. is developing two preclinical programs in the area of Parkinson’s disease. The product candidates in the company’s pipeline emanate from discoveries made using its proprietary drug discovery platform. The company was founded in 1993 and is headquartered in San Diego, California.